micro-community-banner
 
  • Saved

2yr
The Role of Matrix Stiffness in Breast Cancer Progression: a Review

The Role of Matrix Stiffness in Breast Cancer Progression: a Review

Source : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1284926/full

The significance of matrix stiffness in cancer development has been investigated in recent years. The gradual elastic force the extracellular matrix imparts to cells, known as matrix stiffness, is one...

This review describes the mechanical microenvironment in breast cancer, the effect of extracellular matrix stiffness on breast cancer’s biologic behavior and signaling pathway, and transformation treatments for matrix stiffness in breast cancer.

  • Saved

2yr
Research Progress of Claudin-Low Breast Cancer

Research Progress of Claudin-Low Breast Cancer

Source : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1226118/full

Claudin-low breast cancer (CLBC) is a subgroup of breast cancer discovered at the molecular level in 2007.

This article describes the clinicopathologic features of CLBC, which is highly expressed in the immune response, breast cancer stem cells/tumor initiating cells, and EMT-related gene markers.

  • Saved

2yr
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Source : https://pubmed.ncbi.nlm.nih.gov/37775689/

These patients were older than those in the MONARCH studies with substantial visceral disease, and prior chemotherapy and CDK4 & 6i use. Discontinuation rates were higher than in previous real-world...

These patients were older than those in the MONARCH studies with substantial visceral disease, and prior chemotherapy and CDK4 & 6i use. Discontinuation rates were higher than in previous real-world studies (11.9%), highlighting the need for proactive management to optimize outcomes, particularly in older patients with mBC.

  • 2yr
    Verzenio is not easy and for the older patients in particular
  • Saved

2yr

Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis

Source : https://doi.org/10.1016/j.clbc.2023.09.002

The results of the currently ongoing trials with CDK4/6 inhibitors will help obtain additional data to evaluate any differences among the different CDK4/6 inhibitors and clarify the weight of TE adverse events in the benefit/risk balance of this new adjuvant strategy.

  • 2yr
    nothing really new but it was generally associated with Tamoxifen not other agents
  • Saved

2yr
CDK4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: a Rapid Health Technology Assessment

CDK4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: a Rapid Health Technology Assessment

Source : https://journals.lww.com/md-journal/fulltext/2023/10060/cdk4_6_inhibitors_for_hormone.89.aspx

n the clinic. Methods: Depending on the Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions (the Second Edition), a percentage quantitative scoring approach was used to objectively...

Until the clinical studies, guideline recommendations, prices, and many other aspects of this assessment are updated, abemaciclib and palbociclib, which have the top 2 scores, can be used as a priority recommendation for Chinese medical institutions to select CDK4/6 inhibitors and optimize the use of the drug catalog based on the scoring...